Clinical Trials Browser

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06442709 2024-06-04

Combined Anti-IL6R and Anticoagulation Therapy in Advanced NPC Patients

Phase NA Unknown

100 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis

NCT03921671 2024-05-29

RELEVENT

Phase 2 Unknown

60 enrolled

Thoracic

Neoplasm Metastasis, Thymoma

NCT04029181 2024-05-03

ImmunoPET With an Anti-CD8 Imaging Agent

Phase 1/2 Unknown

47 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT03423199 2024-03-22

PATHWAY

Phase 3 Unknown

180 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT05872867 2024-03-12

MK-3475-E90

Phase 1 Unknown

54 enrolled

GastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Clinical Trials

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Combined Anti-IL6R and Anticoagulation Therapy in Advanced NPC Patients

RELEVENT

ImmunoPET With an Anti-CD8 Imaging Agent

PATHWAY

MK-3475-E90

Safety/Tolerability, PK and Efficacy of IMB071703 Injection in Patients With Advanced Solid Tumors

DART

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

MINI-MD

Imaging Guided Cementoplasty for Pelvic Bone Metastasis

68Ga-PSMA PET in the Prostate Cancer

68Ga-GPFAPI

HOLIPANC

PET-MaN

The Effect of Antenatal Education on Fear of Birth, Physiological Ability to Give Birth and Traumatic Birth Perception

CELEBRATE

Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma

Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors

Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors

LoMP

Clinical Study of SM3321 With Solid Tumors

CRLM-Z

Overcome, a Program of Therapeutic Exercise and Functional Recovery to Improve the Functional Capacity of Women With Breast Cancer and Bone Metastases

V-CHANCE

Study of BEBT-607 Tablets in The Treatment of Advanced or Metastatic Solid Tumors With KRAS G12C Mutation

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents

MSCs for the Treatment of Burn Wounds

TWICE-IRI

Minnelide 101

EPOST MBC

PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II Trial

Cognitive Outcome After SRS or WBRT in Patients With Multiple Brain Metastases (CAR-Study B)

Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer

A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

HLX301

HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors

A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors

BRISK

The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment

Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC

A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors

A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations

Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer

PRINCESS

MAP-01

MICRO

SeliGIST